SMMT

ivonescimab

FDA PDUFA Target Action Date · Summit Therapeutics Inc.

Saturday, November 14, 2026

119 days away

Drug Information

Drug Name: ivonescimab (CT.gov)
Application Type: BLA
Indication: EGFR-mutated locally advanced or metastatic non-squamous NSCLC who have received prior EGFR TKI therapy

Filing Details

Company: Summit Therapeutics Inc.
Stock Ticker: SMMT
SEC CIK: 0001599298
Source: SEC EDGAR (LLM-extracted from primary filing) →

What is a PDUFA Date?

A PDUFA (Prescription Drug User Fee Act) date is the FDA's target deadline to complete review of a drug application. The FDA aims to make an approval decision by this date.

Standard Review: 10 months from filing acceptance
Priority Review: 6 months from filing acceptance
Possible Outcomes: Approval, Complete Response Letter (CRL), or extension

Track All FDA Decisions

View all upcoming PDUFA dates and AdCom meetings on our FDA Calendar.

View FDA Calendar →

Data sourced from SEC EDGAR filings. Last updated: 2026-05-10. Report an issue